JTI Appoints New Factory Manager in Switzerland

JTI by 2FIRSTS.ai
Jan.19.2024
JTI Appoints New Factory Manager in Switzerland
Serkan Pusuroglu appointed as the new factory manager of Japan Tobacco International's Dagmersellen plant in Switzerland.

According to a report by Luzerner Zeitung on January 17th, Japan Tobacco International has announced a personnel appointment. Serkan Pusuroglu, the factory manager of Japan Tobacco International's Myanmar factory, will assume the position of factory manager in Dagmersellen, Switzerland.

 

Previously, Piotr Lipinski, former CEO of Daggmercelen, has been appointed as the Global Director of Engineering.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

InterTabac 2025 Insights|RELX Unveils “Vaporless” Showcase Cabinet Featuring Nicotine Airpouch and Prototype Vaporless Device
InterTabac 2025 Insights|RELX Unveils “Vaporless” Showcase Cabinet Featuring Nicotine Airpouch and Prototype Vaporless Device
At InterTabac 2025, RELX’s oral-nicotine showcase featured leaf-shaped Nicotine Airpouch products under the WAKA, RELX, and DOSH brands, alongside a prototype “vaporless oral product.” The device produces no visible aerosol upon exhalation during light puffs and is currently for exhibition only, with no confirmed launch timeline. RELX also displayed a nose-inhaled e-cigarette that differs from conventional mouth-inhaled vaping by requiring nasal inhalation.
Sep.20 by 2FIRSTS.ai
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts Research: VUSE Ultra Promotion in Germany, Free E-Cigarette Kit Worth €24 with Registration
2Firsts discovered during its research in Cologne, Germany, that BAT’s VUSE Ultra is running a promotional campaign. Consumers who register on the VUSE website and enter a dealer code can receive a free e-cigarette kit (including device and pods) worth €24.
Sep.23 by 2FIRSTS.ai
Tobacco harm reduction advocates criticize COP11 for limiting public participation and call for inclusion of harm reduction products in discussions
Tobacco harm reduction advocates criticize COP11 for limiting public participation and call for inclusion of harm reduction products in discussions
The Conference of the Parties to the World Health Organization's Framework Convention on Tobacco Control (COP11) will convene in Geneva in November to discuss global tobacco control policies. Tobacco harm reduction advocates worry that the meeting may only avoid further policy damage without achieving substantive progress. They point out that COP11 limits public participation and call for strengthened discussion on safe nicotine products.
Sep.30 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
Singapore's Narcotics Bureau cracked down on a criminal group smuggling etomidate-containing e-cigarettes for the first time, arresting 8 people and seizing a large number of cartridges
Singapore's Narcotics Bureau cracked down on a criminal group smuggling etomidate-containing e-cigarettes for the first time, arresting 8 people and seizing a large number of cartridges
CNB launches first major operation against e-liquid smuggling group in Singapore, arresting 7 men and 1 woman.
Sep.15 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai